CA2619698A1 - Mutant de p. haemolytica a deletion lkta - Google Patents
Mutant de p. haemolytica a deletion lkta Download PDFInfo
- Publication number
- CA2619698A1 CA2619698A1 CA002619698A CA2619698A CA2619698A1 CA 2619698 A1 CA2619698 A1 CA 2619698A1 CA 002619698 A CA002619698 A CA 002619698A CA 2619698 A CA2619698 A CA 2619698A CA 2619698 A1 CA2619698 A1 CA 2619698A1
- Authority
- CA
- Canada
- Prior art keywords
- haemolytica
- calves
- leukotoxin
- serotype
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001293418 Mannheimia haemolytica Species 0.000 title claims abstract description 107
- 238000012217 deletion Methods 0.000 title description 23
- 230000037430 deletion Effects 0.000 title description 23
- 239000013612 plasmid Substances 0.000 claims description 57
- 230000010076 replication Effects 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 abstract description 61
- 229960005486 vaccine Drugs 0.000 abstract description 49
- 241000283690 Bos taurus Species 0.000 abstract description 17
- 241001494479 Pecora Species 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 241000283707 Capra Species 0.000 abstract description 13
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 abstract description 13
- 241000282849 Ruminantia Species 0.000 abstract description 10
- 230000003115 biocidal effect Effects 0.000 abstract description 4
- 244000309466 calf Species 0.000 description 118
- 101710170970 Leukotoxin Proteins 0.000 description 77
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 72
- 210000004072 lung Anatomy 0.000 description 46
- 238000002255 vaccination Methods 0.000 description 34
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 26
- 229930027917 kanamycin Natural products 0.000 description 25
- 229960000318 kanamycin Drugs 0.000 description 25
- 229930182823 kanamycin A Natural products 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 230000004044 response Effects 0.000 description 22
- 241000894006 Bacteria Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 15
- 230000002949 hemolytic effect Effects 0.000 description 15
- 210000003097 mucus Anatomy 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 241000190661 Mannheimia haemolytica serotype 1 Species 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000011887 Necropsy Methods 0.000 description 11
- 210000002741 palatine tonsil Anatomy 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 206010037660 Pyrexia Diseases 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000007596 consolidation process Methods 0.000 description 7
- 229940126578 oral vaccine Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001989 nasopharynx Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002151 Pleural effusion Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 208000026802 afebrile Diseases 0.000 description 4
- 239000007478 blood agar base Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010003598 Atelectasis Diseases 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 206010035588 Pleural adhesion Diseases 0.000 description 3
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229960000223 tilmicosin Drugs 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 2
- 239000007382 columbia agar Substances 0.000 description 2
- 239000006781 columbia blood agar Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000013029 homogenous suspension Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000027086 plasmid maintenance Effects 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 101100075612 Aggregatibacter actinomycetemcomitans ltxA gene Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000002289 Bovine Respiratory Disease Complex Diseases 0.000 description 1
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 230000002624 leukotoxic effect Effects 0.000 description 1
- 101150108880 lktA gene Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229940028582 micotil Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000822 oral exposure Toxicity 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000030218 transient fever Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6006097P | 1997-09-25 | 1997-09-25 | |
US60/060,060 | 1997-09-25 | ||
CA2303390A CA2303390C (fr) | 1997-09-25 | 1998-09-25 | Mutant de p. haemolytica a deletion lkta |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2303390A Division CA2303390C (fr) | 1997-09-25 | 1998-09-25 | Mutant de p. haemolytica a deletion lkta |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2619698A1 true CA2619698A1 (fr) | 1999-04-01 |
Family
ID=39264363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002619698A Abandoned CA2619698A1 (fr) | 1997-09-25 | 1998-09-25 | Mutant de p. haemolytica a deletion lkta |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2619698A1 (fr) |
-
1998
- 1998-09-25 CA CA002619698A patent/CA2619698A1/fr not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU745003B2 (en) | Live attenuated vaccines | |
US6573093B2 (en) | Temperature sensitive plasmids of P. haemolytica | |
CA2729080C (fr) | Vaccins pour le betail | |
US20190000954A1 (en) | Attenuated mannheimia haemolytica strains | |
Briggs et al. | Mucosal and parenteral vaccination against pneumonic pasteurellosis in cattle with a modified-live in-frame lktA deletion mutant of Mannheimia haemolytica | |
JP3905127B2 (ja) | パスツレラ・ヘモリチカ白血球毒素に対する免疫 | |
US6936262B2 (en) | LktA deletion mutant of P. haemolytica | |
US20010018055A1 (en) | Deletion mutants of virulence factors of pasteurellaceae | |
Briggs et al. | LKTA deletion mutant of P. haemolytica | |
CA2619698A1 (fr) | Mutant de p. haemolytica a deletion lkta | |
MXPA00002975A (en) | Lkta | |
Jablonski | Development of a cloning system for gene expression in Pasteurella multocida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |